J. Grahammer, D. Moser, D. Wolfram, N. Eberhart, B. Zelger, B. Zelger, K. Kotsch, J. Pratschke, S. Schneeberger, T. Hautz
{"title":"Treatment with Local Anti-IL-1ß Prolongs Allograft Survival After Rat Vascularized Composite Allotransplantation","authors":"J. Grahammer, D. Moser, D. Wolfram, N. Eberhart, B. Zelger, B. Zelger, K. Kotsch, J. Pratschke, S. Schneeberger, T. Hautz","doi":"10.4161/23723505.2014.970886","DOIUrl":null,"url":null,"abstract":"Anti-IL-1b was applied in an experimental rat hindlimb transplantation model (Brown Norway (BN) rats to Lewis (LEW) rats). Four different treatment groups included: No treatment (1); baselineimmunosuppression consisting of FK506 30 mg/kg 50 days, ALS 0.5 mL day 0 C 3 (2), baseline immunosuppression C weekly injections of Anti-IL1b subcutaneously (s.c.) into the transplanted limb (3), baselineimmunosuppression C Anti-IL1b s.c. into the contralateral, nontransplanted limb (4). End-point was rejection grade III or postoperative day 100. Graft infiltrating cells were isolated and assessed for T cell populations using flow cytometry. Skin transplantations of BN and 3rd party rats were performed in long-survivors (> 100 days) to assess for tolerance.","PeriodicalId":372758,"journal":{"name":"Vascularized Composite Allotransplantation","volume":"22 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascularized Composite Allotransplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4161/23723505.2014.970886","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Anti-IL-1b was applied in an experimental rat hindlimb transplantation model (Brown Norway (BN) rats to Lewis (LEW) rats). Four different treatment groups included: No treatment (1); baselineimmunosuppression consisting of FK506 30 mg/kg 50 days, ALS 0.5 mL day 0 C 3 (2), baseline immunosuppression C weekly injections of Anti-IL1b subcutaneously (s.c.) into the transplanted limb (3), baselineimmunosuppression C Anti-IL1b s.c. into the contralateral, nontransplanted limb (4). End-point was rejection grade III or postoperative day 100. Graft infiltrating cells were isolated and assessed for T cell populations using flow cytometry. Skin transplantations of BN and 3rd party rats were performed in long-survivors (> 100 days) to assess for tolerance.